Clinical Trials
25 trialsNCT05329766 2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT01142388 2026-05-29
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07603375 2026-05-29
TNT Esophagus
Duke University
Phase 2 Not yet recruiting
NCT06251973 2026-05-15
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07432295 2026-05-14
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT04939051 2026-05-13
Obeticholic Acid for Prevention in Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06732388 2026-05-13
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT02521285 2026-04-29
Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06846346 2026-04-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT04114136 2026-04-24
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
NCT05480384 2026-04-21
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Phase 2 Active not recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT03161522 2026-04-15
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05745857 2026-04-13
SLURP
University Medical Center Groningen
Phase 2 Recruiting
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT07282912 2026-03-04
OLIGOMETS
Yale University
Phase 2 Recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT06330064 2026-02-12
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
Phase 2 Recruiting
NCT04028167 2026-01-09
Induction FLOT With CROSS CRT for Esophageal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT06161818 2025-12-22
TNT-OES-2
Erasmus Medical Center
Phase 2 Recruiting
NCT05563766 2025-11-05
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
VA Office of Research and Development
Phase 2 Recruiting
NCT07222657 2025-10-31
Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06687876 2025-07-10
MEMENTO
Amsterdam UMC, location VUmc
Phase 2 Recruiting